Citations

Clear

3138 citation(s) found for "Smith, AM".

Treatment of urethral stricture disease in women: A multi‐institutional collaborative project from the SUFU research network
Lane, Giulia I. , Smith, Ariana L. , Stambakio, Hanna, Lin, George, Alawamlh, Omar Al Hussein, Anger, Jennifer T. , Brandes, Eileen R., Carmel, Maude , Chung, Doreen E. , Cox, Lindsey , DeLong, Jessica , Eltahawy, Ehab , França, Wagner, Gousse, Angelo E., Gupta, Priyanka , Hagedorn, Judith C. , High, Rachel , Khan, Aqsa , Kowalik, Casey G. , Lee, Richard K., Lucioni, Alvaro , MacDonald, Susan M. , Malaeb, Bahaa S., McKay, Scotty, Padmanabhan, Priya , Powell, Charles R., Sajadi, Kamran P. , Sutherland, Suzette E. , Theva, Didi , Vollstedt, Annah , Welk, Blayne , Zheng, Yu , Cameron, Anne P. , Carmel, Maude E , Elliott, Christopher S , Sajadi, Kamran P , Vollstedt, Annah , Welk, Blayne , Lee, Una J

Mayo Clinic

Neurourology and Urodynamics | September 19, 2020 | Volume: 39 | Issue: 8 | Pages: 2433-2441

10.1002/nau.24507 | PMID 32926460 Get It

Abstract Aim Female urethral stricture disease is rare and has several surgical approaches including endoscopic dilations (ENDO), urethroplasty with local vaginal tissue flap (ULT) or urethroplasty with free graft (UFG). This study aims to describe the contemporary management of female urethral stricture disease and to evaluate the outcomes of these three surgical approaches. Methods This is a multi‐institutional, retrospective cohort study evaluating operative treatment for female urethral stricture. Surgeries were grouped into three categories: ENDO, ULT, and UFG. Time from surgery to stricture recurrence by surgery type was analyzed using a Kaplan–Meier time to event analysis. To adjust for confounders, a Cox proportional hazard model was fit for time to stricture recurrence. Results Two‐hundred and ten patients met the inclusion criteria across 23 sites. Overall, 64% ( n = 115/180) of women remained recurrence free at median follow‐up of 14.6 months (IQR, 3–37). In unadjusted analysis, recurrence‐free rates differed between surgery categories with 68% ENDO, 77% UFG and 83% ULT patients being recurrence free at 12 months. In the Cox model, recurrence rates also differed between surgery categories; women undergoing ULT and UFG having had 66% and 49% less risk of recurrence, respectively, compared to those undergoing ENDO. When comparing ULT to UFG directly, there was no significant difference of recurrence. Conclusion This retrospective multi‐institutional study of female urethral stricture demonstrates that patients undergoing endoscopic management have a higher risk of recurrence compared to those undergoing either urethroplasty with local flap or free graft.
Concussions in Ice Hockey — Moving Toward Objective Diagnoses and Point-of-care Treatment: A Review
Pender, Sara C. , Smith, Aynsley M., Huston, John , Finnoff, Jonathan T. , Stuart, Michael J.

Mayo Clinic

Current Sports Medicine Reports | September 9, 2020 | Volume: 19 | Issue: 9 | Pages: 380-386

10.1249/jsr.0000000000000752 | PMID 32925378 Get It

Abstract The incidence of sport-related concussion coupled with a doubling of the participation rate in youth hockey over the past two decades provides impetus for the review of the most promising concussion treatment options. This narrative review summarizes the future treatment options for sport-related concussions in ice hockey, while acknowledging their generalizability to concussion in all sports. Symptom assessment, sign observation, as well as cognitive and balance testing, have historically been used to diagnose a concussion. These methods continue to improve, but the need for effective treatments is clear. Pharmacologic, transcranial light, and nutritional supplement treatment options for concussion warranting further investigation have been identified. Dimethyl fumarate is an immunomodulatory compound thought to trigger antioxidant gene expression. Memantine reduces apoptosis and astrogliosis by inhibiting the calcium influx into cells normally caused by glutamate's activation of N -methyl- d -aspartate receptors. Thioredoxin-mimetic peptides and transcranial photobiomodulation temper the effects of the energy crisis by acting as free radical scavengers. In addition, seven neuroprotective nutritional supplements have been identified: berberine, creatine, curcumin, melatonin, omega-3 fatty acids, resveratrol, and vitamins. An estimated US $1.1 billion has been spent on unsuccessful traumatic brain injury clinical trials. As our ability to accurately diagnose concussion improves, dimethyl fumarate, memantine, thioredoxin-mimetic peptides, transcranial photobiomodulation, and nutritional supplements (berberine, creatine, curcumin, melatonin, omega-3 fatty acids, resveratrol, and vitamins) warrant further preclinical and clinical examination in advancing the treatment of sport-related concussions.
Hypofractionated Proton Beam Radiotherapy in Patients With Unresectable Liver Tumors: Multi-institutional Prospective Results From the Proton Collaborative Group
Parzen, Jacob S. , Hartsell, William F. , Chang, John P., Molitoris, Jason K. , Durci, Michael, Urbanic, James J., Ashman, Jonathan B. , Vargas, Carlos , Stevens, Craig, Kabolizadeh, Peyman, Apisarnthanarax, Smith , Tsai, Henry K.

Mayo Clinic

No container title available | September 8, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-70862/v1 Get It

Abstract Background: Recent advances in radiotherapy techniques have allowed ablative doses to be safely delivered to inoperable liver tumors. In this setting, proton beam radiotherapy (PBT) provides the means to escalate radiation dose to the target volume while sparing the uninvolved liver. This study evaluated the safety and efficacy of hypofractionated PBT for liver tumors, predominantly hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).Methods: We evaluated the prospective registry of the Proton Collaborative Group for patients undergoing definitive PBT for liver tumors. Demographic, clinicopathologic, toxicity, and dosimetry information were compiled.Results: To date, 63 patients have been treated at 9 institutions between 2013-2019. Thirty (48%) had HCC and 25 (40%) had ICC. The median dose and biological equivalent dose (BED) delivered was 58.05 GyE (range, 32.5-75) and 80.5 GyE (range, 53.6-100), respectively. The median mean liver BED was 13.9 GyE. Three (4.8%) patients experienced at least one grade ³3 toxicity. With median follow-up of 5.1 months (range, 0.1-40.8), the local control (LC) rate at 1 year was 91.2% for HCC and 90.9% for ICC. The 1-year LC was significantly higher (95.7%) for patients receiving BED greater than 75.2 GyE than for patients receiving BED of 75.2 GyE or lower (84.6%, p = 0.029). The overall survival rate at 1 year was 65.6% for HCC and 81.8% for ICC. Conclusions: Hypofractionated PBT results in excellent LC, sparing of the uninvolved liver, and low toxicity, even in the setting of dose-escalation. Higher dose correlates with improved LC, highlighting the importance of PBT especially in patients with recurrent or bulky disease.
Associations of a Metal Mixture Measured in Multiple Biomarkers with IQ: Evidence from Italian Adolescents Living near Ferroalloy Industry
Bauer, Julia A. , Devick, Katrina L. , Bobb, Jennifer F. , Coull, Brent A. , Bellinger, David, Benedetti, Chiara, Cagna, Giuseppa, Fedrighi, Chiara, Guazzetti, Stefano, Oppini, Manuela, Zoni, Silvia, Smith, Donald R. , Lucchini, Roberto G. , Henn, Birgit Claus , Bellinger, David, Placidi, Donatella , Webster, Thomas F. , White, Roberta F. , Yang, Qiong , Wright, Robert O.

Mayo Clinic

Environmental Health Perspectives | September 8, 2020 | Volume: 128 | Issue: 9 | Pages: No page available

10.1289/ehp6803 | PMID 32897104 Get It

C9orf72 poly GA RAN-translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity
Baskaran, Pranetha , Gomez-Deza, Jorge, Chen, Han-Jou, Nishimura, Agnes L. , Adachi, Yoshitsugu, Stepto, Alan, Petrucelli, Leonard , Rogelj, Boris , Guthrie, Sarah , Shaw, Christopher E. , Chen, Han-Jou , Lee, Youn‐Bok , Smith, Bradley , Troakes, Claire , Gallo, Jean‐Marc , Hirth, Frank

Mayo Clinic

Human Molecular Genetics | September 4, 2020 | Volume: 30 | Issue: 3-4 | Pages: 318-320

10.1093/hmg/ddaa181 | PMID 32888026 Get It

NCCN Guidelines Insights: Kidney Cancer, Version 1.2021
Boyle, Shawna, Carlo, Maria I. , Alva, Ajjai , Beckermann, Katy , Choueiri, Toni K. , Costello, Brian A. , Derweesh, Ithaar , Desai, Arpita, Kyriakopoulos, Christos E. , Lau, Clayton, Lewis, Bryan , McCreery, Brittany, Michaelson, M. Dror , Mortazavi, Amir , Nandagopal, Lakshminarayanan , Ponsky, Lee , Ramalingam, Sundhar, Shuch, Brian , Smith, Zachary L. , Somer, Bradley G. , Sosman, Jeffrey A. , Dwyer, Mary A., Motter, Angela D., Choueiri, Toni K , Motzer, Robert J. , Jonasch, Eric W. , Manley, Brandon J. , Agarwal, Neeraj , George, Saby , Gore, John L. , Haas, Naomi B , Hancock, Steven Lee , Lam, Elaine T. , Madoff, David C. , Pierorazio, Phillip , Plimack, Elizabeth R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 4, 2020 | Volume: 18 | Issue: 9 | Pages: 1160-1170

10.6004/jnccn.2020.0043 | PMID 32886895 Get It

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to certain systemic therapy recommendations for patients with relapsed or stage IV RCC. They also discuss the addition of a new section to the guidelines that identifies and describes the most common hereditary RCC syndromes and provides recommendations for genetic testing, surveillance, and/or treatment options for patients who are suspected or confirmed to have one of these syndromes.
Locomotor muscle group III/IV afferents constrain stroke volume and contribute to exercise intolerance in human heart failure
Smith, Joshua R. , Joyner, Michael J. , Curry, Timothy B. , Borlaug, Barry A. , Keller‐Ross, Manda L. , Iterson, Erik H. Van , Olson, Thomas P. , Van Iterson, Erik H , Smith, Joshua R , Borlaug, Barry A , Joyner, Michael J , Keller-Ross, Manda

Mayo Clinic

The Journal of Physiology | September 4, 2020 | Volume: 598 | Issue: 23 | Pages: 5379-5390

10.1113/jp280333 | PMID 32886795 Get It

Key points Heart failure patients with reduced ejection fraction (HFrEF) exhibit severe limitations in exercise capacity ( peak). One of the primary peripheral mechanisms suggested to underlie exercise intolerance in HFrEF is excessive locomotor muscle group III/IV afferent feedback; however, this has never been investigated in human heart failure. HFrEF patients and controls performed an incremental exercise test to volitional exhaustion to determine peak with lumbar intrathecal fentanyl or placebo. During exercise, cardiac output, leg blood flow and radial artery and femoral venous blood gases were measured. With fentanyl, compared with placebo, patients with HFrEF achieved a higher peak workload, peak, cardiac output, stroke volume and leg blood flow. These findings suggest that locomotor muscle group III/IV afferent feedback in HFrEF leads to increased systemic vascular resistance, which constrains stroke volume, cardiac output and O2 delivery thereby impairing peak and thus exercise capacity. AbstractTo better understand the underlying mechanisms contributing to exercise limitation in heart failure with reduced ejection fraction (HFrEF), we investigated the influence of locomotor muscle group III/IV afferent inhibition via lumbar intrathecal fentanyl on peak exercise capacity ( peak) and the contributory mechanisms. Eleven HFrEF patients and eight healthy matched controls were recruited. The participants performed an incremental exercise test to volitional exhaustion to determine peak with lumbar intrathecal fentanyl or placebo. During exercise, cardiac output and leg blood flow () were measured via open‐circuit acetylene wash‐in technique and constant infusion thermodilution, respectively. Radial artery and femoral venous blood gases were measured. peak was 15% greater with fentanyl compared with placebo for HFrEF (P < 0.01), while no different in the controls. During peak exercise with fentanyl, cardiac output was 12% greater in HFrEF secondary to significant decreases in systemic vascular resistance and increases in stroke volume compared with placebo (all, P < 0.01). From placebo to fentanyl, leg , and O2 delivery were greater for HFrEF during peak exercise (all, P < 0.01), but not control. These findings indicate that locomotor muscle group III/IV afferent feedback in patients with HFrEF leads to increased systemic vascular resistance, which constrains stroke volume, cardiac output and O2 delivery, thereby impairing peak and thus exercise capacity. These findings have important clinical implications as peak is highly predictive of morbidity and mortality in HF.
Isolated optic nerve leukemic relapse diagnosed via fine needle aspiration biopsy and transconjunctival biopsy
McInnis‐Smith, Kerri , Mansueto, Lisa A., Schafernak, Kristian T. , Jacobsen, Jeffrey, Henry, M M , Ramasubramanian, Aparna , Henry, Michael M , McInnis-Smith, Kerri M , Schafernak, Kristian

Mayo Clinic

Pediatric Blood & Cancer | September 4, 2020 | Volume: 68 | Issue: 2 | Pages: No page available

10.1002/pbc.28684 | PMID 32886399 Get It

Abstract CT236: A phase 1b, multicenter, randomized, blinded, placebo-controlled study to evaluate the efficacy of guselkumab in subjects with familial adenomatous polyposis
Vilar-Sanchez, Eduardo, Correa, Marcia R. Cruz, Grandval, Philippe , Llor, Xavier , Riegert‐Johnson, Douglas L. , Saurin, Jean‐Christophe , Sussman, Daniel A. , Weinberg, David S. , Attiyeh, Edward F., Joseph, Devanand, Raybold, Kelly, Borzillo, Gary , Smith, Michael , Xie, Hong , Bachman, Kurtis E. , Infante, Jeffrey R., Samadder, N. Jewel , Burke, Carol A. , Dekker, Evelien , Grady, William M. , Katona, Bryson W , Stanich, Peter P. , Prior, Thomas J.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: CT236-CT236

10.1158/1538-7445.am2020-ct236 Get It

Abstract Background: Familial adenomatous polyposis (FAP) is the most common hereditary polyposis syndrome. It is an autosomal dominant inherited disorder characterized by the early onset of hundreds to thousands of adenomatous polyps throughout the colon. If left untreated, nearly all individuals with this syndrome develop colorectal cancer (CRC) by the third decade of life. Prophylactic colectomy is the standard of care, but individuals remain at risk for malignant transformation of duodenal polyps, rectal polyps for those who have undergone rectal-sparing surgeries, and ileal pouch polyps for those with ileal pouch-anal anastomoses. Multiple studies with both nonselective and selective cyclooxygenase inhibitors (such as sulindac or celecoxib) have shown that anti-inflammatory agents may prevent the formation and inhibit the growth of colorectal adenomatous polyps. However, toxicities associated with these agents and their limited efficacy have prevented their further development. Therefore, there is a high unmet need for novel treatment options to reduce polyp burden, delay or eliminate the need for colectomy and recurrent rectal surgery, and intercept the development of adenocarcinomas in individuals with FAP. Polyps from individuals with FAP display inflammatory features associated with the activation of the IL-23/IL-17/JAK/STAT3 pathway. This inflammation is thought to contribute to further carcinogenesis, culminating in tumor development. Specifically, IL-23 is linked to tumor growth and progression in CRC, and adenomas with high-grade dysplasia showed elevated levels of IL-17A and pSTAT3. Guselkumab, a human monoclonal antibody directed against the p19 subunit of IL-23, specifically targets IL-23 and inhibits its interaction with the IL-23 receptor. Pre-clinical models suggest that inhibition of IL-23 signaling will result in less inflammation and reduce tumor development. Methods: This randomized, blind, placebo-controlled study will evaluate the safety and efficacy of guselkumab in adults with FAP (genetic or clinical diagnosis) who have already undergone colectomy. Polyps with a sum of diameters ≥10 mm in the rectum or pouch are required. Subjects will be randomized equally to one of three study arms: 100 mg, 300 mg, or placebo given subcutaneously every 4 weeks for 6 doses. The primary efficacy endpoint is percentage change from baseline in rectal/pouch polyp burden after 24 weeks. Secondary efficacy endpoints include duodenal polyp burden change and changes in InSiGHT and Spigelman staging. Exploratory translational research objectives will explore changes in RNA expression profiles, epigenomic profiles, cytokine levels, and the microbiome. Exclusion criteria include prior IL-23 targeted therapies and any polyps &gt;1 cm that cannot be removed. While participating, subjects are required to stop any other FAP-directed drug therapy except for aspirin. As of January 2019, 18% of the planned 72 subjects have been enrolled. ClinicalTrials.gov Identifier: NCT03649971. Citation Format: Eduardo Vilar-Sanchez, Carol Burke, Marcia R. Cruz Correa, Evelien Dekker, William M. Grady, Philippe Grandval, Bryson W. Katona, Xavier Llor, Douglas L. Riegert-Johnson, Jean-Christophe Saurin, Peter Stanich, Daniel A. Sussman, David Weinberg, Edward F. Attiyeh, Devanand Joseph, Kelly Raybold, Gary V. Borzillo, Thomas J. Prior, Michael Smith, Hong Xie, Kurtis E. Bachman, Jeffrey R. Infante, Niloy Jewel Samadder. A phase 1b, multicenter, randomized, blinded, placebo-controlled study to evaluate the efficacy of guselkumab in subjects with familial adenomatous polyposis [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT236.